Last month, the best and brightest minds in oncology gathered (virtually) for the American Society of Clinical Oncology (ASCO) annual conference. The conference was ablaze…

Two of Prescient Therapeutics’ (PTX) assets have been handpicked for a COVID-19 antiviral testing program. The trial, run by the renowned Doherty Institute, will take…

Prescient Therapeutics Limited (ASX:PTX) has signed a research agreement with the Peter Doherty Institute for Infection and Immunology subsequent to the selection of two existing assets of…

Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has revealed two of its assets have been selected as group one priority candidates for a COVID-19 antiviral testing…

PTX has acquired the exclusive global licence to a universal immune receptor (UIR) platform from the University of Pennsylvania (Upenn) and a non-exclusive licence to…

Prescient Therapeutics (ASX: PTX) CEO and Managing Director Steven Yatomi-Clarke joined Steve Darling from Proactive to share details about the company that is personalizing cancer…

Capital dedicated by local investors to risky investments that was once largely tied up in junior explorers is starting to flow to early-stage biotech companies,…

ASX listed biotech company Prescient Therapeutics (ASX: PTX) has this week unveiled two significant licence agreements that forms the IP backbone of its work into…

OmniCAR could answer many questions for first-gen CAR-T approaches. Last night, Australian based Prescient hosted an investor call, and announced a licensing agreement with U….

Biotech company Prescient Therapeutics (ASX: PTX) emerged from a trading halt this morning to unveil two significant licences related to its universal immune receptor technology platform, currently…